Cancel

Update in Food Allergy Management

Target Audience This activity has been designed to address the educational needs of pediatric nurse practitioners, pediatricians, and allergists. It may also benefit other clinicians interested in the management of food allergy (FA). Program Overview New insights into the immunopathology of FA have led to development of cautious use of controlled exposure to food allergens through allergen immunotherapy and emerging use of monoclonal antibody therapy to interfere with the synthesis of imm...
Paradigm Medical Communications, LLC.

Recent Developments in the Treatment of Clear Cell, Renal Cell Carcinoma: Essential Insights and Updates for the Healthcare Team

Target Audience Oncology, Managed care and Specialty Pharmacists and Oncology Nurses/Nurse Practitioners Program Overview The goal of this educational initiative is to equip oncology nurse practitioners and nurses, as well as oncology, managed care, and specialty care pharmacists with the knowledge to apply findings from risk scoring systems used to stratify cases of clear cell renal cell carcinoma for treatment selection, differentiate among an expanding array of combination regimens con...
Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).

Gastroenterology 2025 - LIVE STREAMING

The Comprehensive 2025 Gastroenterology Update This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians. Practical, Results-Driven Education Highlights of the 2025 program include: • The new...
Harvard Medical School

Beyond Avoidance: IgE-Mediated Food Allergies " Therapeutic Innovations to the Rescue

In the United States, food-induced allergic reactions are the leading cause of anaphylaxis in hospital emergency departments. Among these, immunoglobulin E (IgE)-mediated food allergies are the most common, and they pose significant risks, including cardiac arrest and respiratory failure. Traditionally, treatment options for IgE-mediated food allergies have been primarily limited to food avoidance and anaphylaxis prevention. However, recent years have brought the FDA approval of the first oral...
Vindico Medical Education

Management of Metastatic Colorectal Cancer

Stacey Cohen, MD, explores the significance of molecular profiling and tumor markers in personalizing immunotherapy for metastatic colorectal cancer. She also delves into the evolving landscape of targeted therapies, discussing the nuances and considerations of different options to optimize patient outcomes.
Annenberg Center for Health Sciences at Eisenhower

Advances in Recurrent/Metastatic Nasopharyngeal Carcinoma: Immunotherapy and Biomarkers

Target Audience This activity was developed for medical oncologists, head and neck surgeons, radiation oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients diagnosed with metastatic nasopharyngeal carcinoma (NPC). Program Overview Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has change...
Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentiali

Toxicity Management and Symptom Control in Advanced RCC: Playbook Update

STATEMENT OF NEED Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standard...
i3 Health

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map